Second-line treatment strategy following CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer patients: a multicentric, retrospective, observational study
Breast Cancer Research and Treatment · 2026
DOI: 10.1007/s10549-025-07893-2 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Breast Cancer Research and Treatment, 2026. Verfasst von Olivia Lavigne und 12 weiteren Autor:innen. Beteiligte Einrichtung: Nîmes University Hospital, Nîmes, France. olivia.lavigne@chu-nimes.fr. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Protein Kinase Inhibitors, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 27 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: The standard first-line treatment for patients with hormone receptor-positive (HR +) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer is cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy (ET). Optimal therapy after CDK4/6 inhibitors remains to be determined. We aimed to define the appropriate second-line treatment after CDK4/6 inhibitors in a real-life population. METHODS: Patients who had received CDK4/6 inhibitors with aromatase inhibitors (AIs) for HR + /HER2- metastatic breast cancer were included from March 2017 to May 2021 at five French cancer centers.The primary objective was to describe second-line treatment after primary treatment with CDK4/6 inhibitors plus AIs. RESULTS: We included 381 patients who received CDK4/6 inhibitors combined with AIs as first-line therapy. Patients with progressive disease (N = 165) benefited from a second-line of treatment: 69 (41.8%) were treated with chemotherapy, while 90 (54.6%) received endocrine therapy (ET alone: 59, 35.8%; ET plus targeted therapy: 31, 18.8%).Patients on chemotherapy were younger compared to those receiving ET (p = 0.011). Patients experiencing earlier progression were more likely to benefit from chemotherapy than ET (p = 0.001). Patients with visceral disease at diagnosis were more often treated with chemotherapy. Second-line median PFS was 6.4 months (95% CI [5.0-12.9]) for chemotherapy and 8.4 months (95% CI [5.4-11.7]) for ET ± targeted therapy, with no significant difference (HR 1.08, 95% CI [0.73-1.59], p = 0.70). CONCLUSION: This French real-world study demonstrates limited progression-free survival benefits across all second-line strategies after CDK4/6 inhibitor progression, highlighting an urgent clinical need for more effective post-progression therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nîmes University Hospital, Nîmes, France. olivia.lavigne@chu-nimes.fr.
- Oncopole Claudius Régaud, Toulouse, France.
- Department of Medical Oncology, Hospices Civils de Lyon (HCL), Lyon, France.
- Medical Oncology Department 1, Hue Central Hospital, Hue City, Vietnam.
- Montpellier Cancer Institute, Montpellier, France.
- INSERM U1194, Montpellier University, Montpellier, France.
Zitieren
APA
Lavigne, O., Poumeaud, F., Reverdy, T., Huynh, V. T., Roces, G., Poupin, G., Gouillou, M., Bobrie, A., Donadille, E., Dalenc, F., Jacot, W., Robert, J., & Fiteni, F. (2026). Second-line treatment strategy following CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer patients: a multicentric, retrospective, observational study. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-025-07893-2
Vancouver
Lavigne O, Poumeaud F, Reverdy T, Huynh VT, Roces G, Poupin G, et al. Second-line treatment strategy following CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer patients: a multicentric, retrospective, observational study. Breast Cancer Research and Treatment. 2026. doi:10.1007/s10549-025-07893-2
BibTeX
@article{Lavigne2026,
author = {Lavigne, Olivia and Poumeaud, François and Reverdy, Thibaut and Huynh, Van Tuat and Roces, Guillaume and Poupin, Gaulthier and Gouillou, Maureen and Bobrie, Angélique and Donadille, Emma and Dalenc, Florence and Jacot, William and Robert, Julien and Fiteni, Frédéric},
title = {Second-line treatment strategy following CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer patients: a multicentric, retrospective, observational study},
journal = {Breast Cancer Research and Treatment},
year = {2026},
doi = {10.1007/s10549-025-07893-2}
}
EUVIMED